[
  {
    "ts": null,
    "headline": "Sage Therapeutics: Looks Like A 'Strong Buy' With Zurzuvae's Potential And Biogen's Bid",
    "summary": "Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE stock is a good buy at these levels.",
    "url": "https://finnhub.io/api/news?id=93f960e9ee058140712fad5946ae153b0689824b4b7841b8225a43c78b91f5c6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737535848,
      "headline": "Sage Therapeutics: Looks Like A 'Strong Buy' With Zurzuvae's Potential And Biogen's Bid",
      "id": 132442317,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1347295696/image_1347295696.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE stock is a good buy at these levels.",
      "url": "https://finnhub.io/api/news?id=93f960e9ee058140712fad5946ae153b0689824b4b7841b8225a43c78b91f5c6"
    }
  }
]